

Key Information Document

PURPOSE

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

PRODUCT

BEST TURBO Warrant (Call) relating to a share of Unitedhealth Group Incorporated (non quanto)

ISIN: DE000FD7VSZ9 / **WKN:** FD7VSZ

MANUFACTURER: Société Générale / www.warrants.com / call +49 (0) 69 7174 825 for more information

COMPETENT AUTHORITY OF THE MANUFACTURER: Autorité des Marchés Financiers (AMF) & Autorité de Contrôle Prudentiel et de Résolution (ACPR), France, are responsible for supervising Société Générale in relation to this Key Information Document

DATE OF PRODUCTION OF THE KEY INFORMATION DOCUMENT: 24 July 2026

ISSUER: Société Générale Effekten GmbH / **GUARANTOR:** Société Générale

You are about to purchase a product that is not simple and may be difficult to understand.

WHAT IS THIS PRODUCT?

Type

This product is a bearer bond governed by and construed in accordance with German law.

Term

The product does not have a fixed term. In addition to selling the product through the exchange where the product is listed or off-exchange you may exercise the product on an Exercise Date. The issuer may ordinarily terminate the product on any Ordinary Termination Date. The product will expire if a Knock-out Event occurs.

Objectives

Objective of the product is to provide you with a specified entitlement according to predefined conditions. You will participate disproportionately (in a leveraged manner) in any price trend of the Underlying.

The product will expire if a Knock-out Event occurs. A Knock-out Event occurs if during the Monitoring Period the Price of the Underlying is at least once equal to or below the applicable Knock-out Barrier. In this case, the product expires immediately worthless.

You may exercise the product on an Exercise Date. The issuer may ordinarily terminate the product on an Ordinary Termination Date.

If no Knock-out Event has occurred and the option right has been validly exercised or the product has been ordinarily terminated by the issuer, you will receive the Redemption Amount on the Settlement Date which shall be equal to (i) the amount by which the Reference Price of the Underlying on the Valuation Date exceeds the Strike applicable on the Valuation Date multiplied by (ii) the Ratio, the result being converted into the Issue Currency.

The Strike is adjusted daily by an adjustment amount which contains a financing component incurred by the Issuer due to the financing of the leverage in the product. The adjustment amount comprises a specific market interest plus a risk premium determined by the Issuer in its reasonable discretion.

The Knock-out Barrier will always correspond to the current Strike.

In addition, upon payment of a dividend by the Underlying's issuer the applicable Strike and the Knock-out Barrier will be reduced by an amount which takes into account the dividend paid net of any taxes or other fees and costs.

The conversion into the Issue Currency shall be made at the conversion rate on the Valuation Date.

You have no right to any entitlement resulting from the Underlying (e.g. dividend payments, voting rights).

Underlying:	Share of Unitedhealth Group Incorporated (ISIN US91324P1021)	Launch Date:	25 June 2026
Exchange:	New York Stock Exchange, Inc.	Payment Date:	29 June 2026
Currency of the Underlying:	United States Dollar (USD)	Monitoring Period:	The period from the Launch Date (starting at 10:48:55 am local time Frankfurt am Main) to the Valuation Date (including).
Currency of the Product (Issue Currency):	Euro (EUR)	Valuation Date:	<i>In case of an exercise:</i> the Exercise Date <i>In case of an ordinary termination:</i> the Ordinary Termination Date
Type of Product:	Call	Exercise Date:	The last payment business day of each month.
Ratio:	0.01	Ordinary Termination Date:	Any payment business day (with at least 28 days prior notice).
Current Strike:	USD 328.736279	Settlement Date:	Not later than on the fifth payment business day following the Valuation Date.
Current Knock-out Barrier:	USD 328.736279	Type of Settlement:	Cash
Reference Price of the Underlying:	The price of the Underlying last determined and published by the Exchange on any relevant day (closing price).	Type of Exercise:	Bermudan (i.e. exercise can take place on each Exercise Date)
Price of the Underlying:	The price of the Underlying as determined and published by the Exchange.	Minimum Exercise Units:	1 product

The Issuer is entitled to terminate the product with immediate effect, if an extraordinary event occurs. Examples of extraordinary events include the delisting or loss of the Underlying, changes in legislation, tax events and the discontinuation of the Issuer's ability to carry out the necessary hedging transactions. In the case of any termination, the termination amount may possibly be significantly below the purchase price. A total loss of the investment is even possible. You also bear the risk that the product will be called in at a time unfavourable to you, and you may only be able to reinvest the termination amount on less favourable terms.

Intended retail investor

The product is aimed at retail clients who pursue the objective of over-proportional participation in price changes and/or hedging and have a short-term investment horizon. This product is a product for clients with comprehensive knowledge of and / or experience with financial products. The investor can bear losses (up to the total loss of the investment amount) and attaches no importance to a capital protection.

WHAT ARE THE RISKS AND WHAT COULD I GET IN RETURN?

Summary Risk Indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 7 out of 7, which is the highest risk class. This rates the potential losses from future performance at a very high level, and poor market conditions are very unlikely to impact our capacity to pay you.

This product does not include any protection from future market performance so you could lose some or all of your investment. If we are not able to pay you what is owed, you could lose your entire investment.

Performance Scenarios

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted. The scenarios shown are illustrations based on results from the past and on certain assumptions. Markets could develop very differently in the future.

Recommended holding period: Example Investment:		1 calendar day (sample period) EUR 10,000 If you exit at the end of the recommended holding period
Scenarios		
Minimum	There is no minimum guaranteed return. You could lose some or all of your investment.	
Stress	What you might get back after costs Percentage return (not annualized)	EUR 3,171 -68.3%
Unfavourable	What you might get back after costs Percentage return (not annualized)	EUR 9,151 -8.5%
Moderate	What you might get back after costs Percentage return (not annualized)	EUR 9,962 -0.4%
Favourable	What you might get back after costs Percentage return (not annualized)	EUR 10,736 7.4%

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back. The stress scenario shows what you might get back in extreme market circumstances. The scenarios shown represent possible outcomes calculated based on simulations.

WHAT HAPPENS IF SOCIÉTÉ GÉNÉRALE IS UNABLE TO PAY OUT?

If the Issuer defaults you may only claim any unpaid amount from Société Générale (the Guarantor). Should Société Générale default or file for bankruptcy, you may suffer a partial or total loss of the invested amount. If the senior non preferred liabilities (pursuant to Article L 613-30-3-1-3° of the French Monetary and Financial Code) of Société Générale becomes subject to resolution measures in the form of the bail-in tool ("bail-in") by reduction to zero, conversion into equity or maturity postponement, your claim on the Issuer shall be limited and reduced to the amounts of principal and/or interest that would be recoverable by the securityholders and/or the value of the shares or other securities or other obligations of Société Générale or another person that would be delivered to the securityholders if the securities had been directly issued by Société Générale itself, and any obligations under the securities had accordingly been directly subject to the exercise of the bail-in. Please be aware that your Investment is not covered by any investor compensation or guarantee scheme. Please find the ratings of Société Générale at <https://investors.societegenerale.com/en/financial-and-non-financial-information/ratings/credit-ratings>.

WHAT ARE THE COSTS?

The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.

Costs over Time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest and how long you hold the product. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- You would get back the amount that you invested (0% annual return).
- EUR 10,000 is invested.

	If you exit at the end of the recommended holding period
Total costs	EUR 39
Cost impact (*)	0.4%

(*) This illustrates the effect of costs over a holding period of less than one year. This percentage is calculated considering the aggregated cost in the period divided by the investment amount and cannot be directly compared to the cost impact figures provided for other products.

Composition of Costs

One-off costs upon entry or exit		If you exit at the end of the recommended holding period
Entry costs	These costs are already included in the price you pay.	EUR 336
Exit costs	These costs are already deducted from the price you receive.	EUR -301
Ongoing costs relating to the recommended holding period		
Management fees and other administrative or operating costs	0.04% of the value of your investment relating to the recommended holding period. This is an estimate based on actual costs.	EUR 4

HOW LONG SHOULD I HOLD IT AND CAN I TAKE MONEY OUT EARLY?

Recommended holding period: 1 calendar day (sample period)

It is not possible to make an individual recommendation to a holding period. The product reacts due to its leverage to smallest price movements of the Underlying leading to losses or profits within unpredictable time periods. Any individual recommendation regarding the holding period would be misleading information for a speculative investor. For investors purchasing the product for hedging purposes the holding period depends on the hedging horizon of the individual investor.

In addition to selling the product through the exchange where the product is listed or off-exchange you may exercise the product on an Exercise Date by transmission of an Exercise Notice to the paying agent. You must instruct your depository bank, which is responsible for the order of the transfer of the specified products. Upon effective exercise you will receive a Redemption Amount as described in more detail under "What is this product?" above. If you should exercise or sell the product before or after the end of the recommended holding period, the amount you will receive could be – even significantly – lower than the amount you would have otherwise received..

Exchange Listing(s)	Hannover Stock Exchange - Open Market (Freiverkehr) and Stuttgart Stock Exchange (Baden-Württembergische Wertpapierbörse) - Regulated Unofficial Market (Freiverkehr)	Smallest Tradable Unit	1 product
		Price Quotation	Unit quotation

In unusual market situations, or in the event of technical faults/disruptions, a purchase and/or sale of the product can be temporarily hindered, or may not be possible at all.

HOW CAN I COMPLAIN?

Any complaint regarding the person advising on, or selling, the product can be submitted directly to that person via the relevant website. Any complaint regarding the product or the conduct of the Issuer of this product can be submitted in text form (e.g. by letter or e-mail) to Société Générale under the following address: SOCIETE GENERALE, Regulatory Information Department, 17 cours Valmy, 92987 PARIS LA DEFENSE CEDEX, FRANCE, or email: info@sgbourse.fr or www.warrants.com.

OTHER RELEVANT INFORMATION

The latest Key Information Document is available online at www.warrants.com. This document may be updated since the date of its creation. The prospectus, any supplements thereto and the final terms are published on the website of Société Générale (www.warrants.com; prospectus and supplements in section Legal documents / Prospectuses; final terms by entering the ISIN into the search field and then in section Documentation), all in accordance with legal requirements. In order to obtain more detailed information - and in particular details of the structure of and risks associated with an investment in the product - you should read these documents.